Literature DB >> 10525974

Long-term recovery and fellow eye deterioration after optic neuritis, determined by serial visual evoked potentials.

A Brusa1, S J Jones, R Kapoor, D H Miller, G T Plant.   

Abstract

Twelve optic neuritis patients (part of a larger group in whom the effects of intravenous methylprednisolone treatment were previously reported), were followed-up 3 years from the onset of symptoms with visual evoked potentials (VEPs), contrast sensitivity and visual field examination. Findings from the previously "unaffected" eyes, none of which had had symptomatic optic neuritis, were also assessed. Between 6 months and 3 years after the onset of symptoms the VEPs of the affected eyes showed a significant shortening of mean latency (whole field, 131-123 ms; central field, 136-125 ms). Conversely, the responses of the previously unaffected eyes showed a contemporaneous latency prolongation (significant for the whole field, 110-113 ms) which exceeded the expected effect of aging. Contrast sensitivity tests showed no significant change in the affected eyes but a mild deterioration in the unaffected eyes, while the visual fields showed no overall pattern of improvement or deterioration. If the strong tendency for VEP latencies to shorten is due to ongoing remyelination, the lack of significant improvement in visual function may be because the visual deficit at 6 months is due to irreversible axonal loss rather than demyelination. The absence of functional deterioration in the affected eye, while VEPs and contrast sensitivity deteriorated in the unaffected eye, suggests that long-term remyelination may for a while counteract the effects of insidious demyelination and axonal degeneration which affect the visual pathway during clinical remission.

Entities:  

Mesh:

Year:  1999        PMID: 10525974     DOI: 10.1007/s004150050454

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  Variation of visual evoked potential delay to stimulation of central, nasal, and temporal regions of the macula in optic neuritis.

Authors:  S Rinalduzzi; A Brusa; S J Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

2.  Normalisation of visual evoked potentials after optic neuritis.

Authors:  Rudy R Hidajat; David H Goode
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 3.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

Review 4.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Independent patterns of damage to retinocortical pathways in multiple sclerosis without a previous episode of optic neuritis.

Authors:  Aldina Reis; Catarina Mateus; M Carmo Macário; José R Faria de Abreu; Miguel Castelo-Branco
Journal:  J Neurol       Date:  2011-03-31       Impact factor: 4.849

6.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

7.  Assessing visual pathway function in multiple sclerosis patients with multifocal visual evoked potentials.

Authors:  Michal Laron; Han Cheng; Bin Zhang; Jade S Schiffman; Rosa A Tang; Laura J Frishman
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

8.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

9.  Mechanism of delayed conduction of fellow eyes in patients with optic neuritis.

Authors:  Daniah Alshowaeir; Con Yiannikas; Clare Fraser; Alexander Klistorner
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

10.  Longitudinal Evaluation of Visual Function in Multiple Sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Optom Vis Sci       Date:  2015-10       Impact factor: 1.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.